Please check your internet connection and try again.
## Ecospirin (Aspirin Enteric-Coated)
### Overview
Ecospirin is an enteric-coated formulation of aspirin, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and antiplatelet properties. The enteric coating is designed to delay the release of aspirin until it reaches the small intestine, potentially reducing gastric irritation.
### Primary Indications
* Pain relief (mild to moderate)
* Fever reduction
* Inflammation reduction
* Prevention of cardiovascular events (e.g., myocardial infarction, stroke) in patients at risk.
* Treatment of Kawasaki disease.
### Adult Dosing
* **Pain and Fever:** 325 mg to 650 mg every 4 to 6 hours as needed. Maximum dose typically 4000 mg daily.
* **Cardiovascular Prevention:** 75 mg to 325 mg once daily. Specific dose depends on clinical indication and risk assessment.
* **Kawasaki Disease (Acute phase):** 80 mg/kg/day divided into 4 doses.
* **Kawasaki Disease (Post-acute phase):** 3 mg/kg/day once daily.
### Pediatric Dosing
* **Pain and Fever:** 10 mg/kg/dose to 15 mg/kg/dose every 4 to 6 hours. Maximum dose typically 4000 mg daily. **Caution:** Aspirin use in children and adolescents with viral infections is associated with Reye's syndrome and should be avoided unless specifically indicated and no alternatives are available.
* **Kawasaki Disease (Acute phase):** 80 mg/kg/day divided into 4 doses.
* **Kawasaki Disease (Post-acute phase):** 3 mg/kg/day once daily.
### Dose Adjustments
No specific dose adjustments are typically required for renal or hepatic impairment, but caution is advised due to potential for accumulation and increased adverse effects.
### Contraindications
* Known hypersensitivity to aspirin, salicylates, or NSAIDs.
* History of bronchospasm, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
* Active peptic ulcer disease or gastrointestinal bleeding.
* Bleeding disorders.
* Severe hepatic or renal impairment.
* Use in children and adolescents with viral illnesses (risk of Reye's syndrome).
### Adverse Effects
* **Gastrointestinal:** Dyspepsia, nausea, vomiting, abdominal pain, GI bleeding, ulceration.
* **Hematologic:** Increased bleeding time, bruising.
* **Auditory:** Tinnitus, hearing loss (especially at higher doses).
* **Renal:** Renal dysfunction.
* **Hypersensitivity:** Asthma exacerbation, urticaria, angioedema.
* **Reye's Syndrome:** In children and adolescents with viral infections.
### Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding.
* **Other NSAIDs and Salicylates:** Additive GI toxicity and increased risk of bleeding.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **Methotrexate:** Aspirin can decrease methotrexate clearance and increase toxicity.
* **Antihypertensives (e.g., ACE inhibitors, ARBs, beta-blockers):** Aspirin may reduce their efficacy.
* **Uricosuric agents (e.g., probenecid):** Aspirin can antagonize the uricosuric effect.
### Monitoring
* Signs and symptoms of GI bleeding (e.g., melena, hematemesis, abdominal pain).
* Signs and symptoms of bleeding or bruising.
* Renal function and liver function, especially with long-term or high-dose use.
* Tinnitus or hearing changes.
* For cardiovascular indications: adherence and clinical outcomes.
### Clinical Pearls
* The enteric coating reduces but does not eliminate the risk of GI side effects. Advise patients to take with food or milk if gastric upset occurs.
* Aspirin should be discontinued at least 5-7 days before elective surgery due to its antiplatelet effect.
* For pain and fever, lower doses are generally preferred. Higher doses are typically used for antiplatelet therapy.
* If managing pain and fever in children, especially with suspected viral illness, consider alternative agents like acetaminophen or ibuprofen.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines before making any treatment decisions.
